What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2025-11-14 compared with 2025-08-18 · 52 added, 6 removed, 20 unchanged (74% of the section changed)

9 unchanged sentences

The issuance of shares

in connection with the Offering and the resale of a significant number of shares by the selling stockholders, or the perception that such

sales may occur, could adversely affect the market price of our common stock.

During the Inducement Period,

in connection with the Offerings and the resale of a significant number of shares by the Holders, or the perception that such sales may

occur, could adversely affect the market price of our common stock.

During the Inducement Periods,

we issued to the Holders New Warrants exercisable for an aggregate of 4,566,391 shares of common stock in exchange for the cash exercise

4 unchanged sentences

in substantial dilution to our existing stockholders and negatively affect the market price of our common stock.

In addition, sales by the Holders

of a significant number of shares of common stock, or the perception that such sales could occur, could materially adversely affect the

trading price of our common stock.

In addition, sales by the

Holders of a significant number of shares of common stock, or the perception that such sales could occur, could materially adversely affect

the trading price of our common stock.

Even if the Holders do not sell their shares immediately, the registration of such shares for resale

2 unchanged sentences

or the availability of shares for sale will have on the trading price of our common stock.

Sales of a substantial

number of shares of our common stock, including those issued pursuant to the Sales Agreement, could cause the market price of our common

stock to decline.

The sale of a substantial

number of shares of our common stock in the public market, or the perception that such sales may occur, could cause the market price of

our common stock to decline.

Although we cannot predict the exact number of shares that may be sold pursuant to the Sales Agreement or

the price at which any sales may occur, the issuance and sale of up to $18,000,000 of our common stock pursuant to the Sales Agreement

may result in the issuance of 10,285,714 additional shares (based on an assumed offering price of $1.75 per share, the closing price of

our common stock on the NYSE American on August 7, 2025).

Based on our shares outstanding as of August 7, 2025, and assuming full issuance

of such shares, we would have 41,909,790 shares of common stock outstanding (excluding any shares issuable upon the conversion or exercise,

as applicable, of outstanding preferred stock, warrants, or stock options).

A substantial majority of the outstanding shares of our common

stock are, and all of the shares sold in this offering upon issuance will be, freely tradable without restriction or further registration

under the Securities Act, unless such shares are owned or purchased by “affiliates” as that term is defined in Rule 144

under the Securities Act.

In addition, as of August

7, 2025, there were outstanding (i) 642,500 shares of Series A convertible preferred stock convertible into an aggregate of 2,294,643

shares of common stock, (ii) warrants to purchase an aggregate of 9,490,184 shares of common stock, and (iii) options to purchase

an aggregate of 2,735,000 shares of our common stock, of which options to purchase 795,000 shares of our common stock were then exercisable.

The shares of our common stock issuable upon conversion or exercise, as applicable, of such securities may be immediately eligible for

resale in the open market.

Any such sales, or the perception that such sales could occur, could cause the market price of our common stock

to decline and may make it more difficult for us to raise capital in the future.

It is not possible

to predict the aggregate proceeds resulting from sales made under the Sales Agreement.

Subject to certain limitations

in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Sales Agents at

any time throughout the term of the Sales Agreement.

The number of shares that are sold through the Sales Agents, if any, after delivering

a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the sales period,

the limits we set with the Sales Agents in any applicable placement notice, and the demand for our common stock during the sales period.

Because the price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the aggregate

proceeds to be raised in connection with those sales.

The common stock offered

hereby will be sold in “at the market offerings,” and investors who buy shares at different times will likely pay different

Investors who purchase shares

pursuant to the Sales Agreement at different times will likely pay different prices, and so may experience different levels of dilution

and different outcomes in their investment results.

We will have discretion, subject to market demand, to vary the timing, prices, and

number of shares sold pursuant to the Sales Agreement.

In addition, subject to the final determination by our board of directors, there

is no minimum or maximum sales price for shares to be sold pursuant to the Sales Agreement.

Investors may experience a decline in the

value of the shares they purchase pursuant to the Sales Agreement as a result of sales made at prices lower than the prices they paid.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors